FINWIRES · TerminalLIVE
FINWIRES

United Therapeutics Growth Outlook Remains Supported by Tyvaso, Ralinepag, RBC Says

By

United Therapeutics (UTHR) still has a stronger long-term growth path despite a soft Q1, helped by Tyvaso durability, possible idiopathic pulmonary fibrosis expansion, TreSMI filing plans, and future upside from ralinepag, RBC Capital Markets said in a note emailed Thursday.

The investment firm said Tyvaso revenue missed estimates in Q1, but the firm expects the franchise to return to growth after weather issues and specialty pharmacy delays subside.

IPF could become the company's next major growth driver, with a supplemental application still planned for this summer and other faster approval paths under review, RBC said.

TreSMI remains on track for a US Food and Drug Administration filing in pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease by year's end, which could help United Therapeutics defend its position in inhaled treprostinil, according to the note.

Ralinepag Dry Powder Inhalation could add longer-term upside because once daily dosing may help the company compete better in pulmonary hypertension and related lung disease markets, RBC added.

RBC lowered its price target for United Therapeutics to $701 from $707 while keeping its outperform rating.

Price: $576.22, Change: $-20.55, Percent Change: -3.44%

Related Articles

Wire

Fastly Swings to Q1 Adjusted Earnings as Revenue Rises; Shares Tumble After Hours

Fastly (FSLY) reported Q1 adjusted earnings late Wednesday of $0.13 per diluted share, compared with the loss of $0.05 a year earlier.Analysts polled by FactSet expected earnings of $0.08.Revenue in the three months ended March 31 rose to $173 million from $144.5 million a year earlier.Analysts surveyed by FactSet expected $171.8 million.Fastly expects Q2 non-GAAP net income of $0.05 to $0.08 a share on revenue of $170 million to $176 million. Analysts polled by FactSet project EPS of $0.04 on revenue of $169.8 million.The company expects full-year non-GAAP net income of $0.27 to $0.33 a share on revenue of $710 million to $725 million. Analysts project EPS of $0.27 on revenue of $712 million.Fastly shares tumbled 28% in after-hours trading.

$FSLY
Wire

Tutor Perini Q1 Adjusted Earnings, Revenue Rise; Shares Fall After Hours

Tutor Perini (TPC) reported Q1 adjusted earnings late Wednesday of $1.03 per diluted share, up from $0.65 a year earlier.Four analysts polled by FactSet expected $0.95.Revenue in the three months ended March 31 rose to $1.39 billion from $1.25 billion a year earlier.Four analysts surveyed by FactSet expected $1.44 billion.The company affirmed its full-year adjusted EPS guidance of $4.90 to $5.30. Analysts expect $5.Tutor Perini shares fell 6.6% in after-hours trading.

$TPC
Wire

Murphy Oil Q1 Adjusted Earnings Fall, Revenue Rises

Murphy Oil (MUR) reported Q1 adjusted earnings late Wednesday of $0.32 per diluted share, down from $0.56 a year earlier.Analysts polled by FactSet expected $0.32.Revenue in the three months ended March 31 rose to $733.6 million from $665.2 million a year earlier.Analysts surveyed by FactSet expected $703 million.Murphy shares fell 2.3% in after-hours trading.

$MUR